<DOC>
	<DOCNO>NCT00683306</DOCNO>
	<brief_summary>The purpose study provide gefitinib treatment patient , completion closure gefitinib clinical study , either receive placebo treatment , continue dose regimen gefitinib establish precede study , long patient continue derive benefit .</brief_summary>
	<brief_title>Open Label Extension Study With Gefitinib ( IRESSAâ„¢ ) Completing Trial Patients Who May Benefit From Further Treatment</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Gefitinib</mesh_term>
	<criteria>Patients complete precede gefitinib therapy either 1839IL/0709 ( 250mg dose ) study 1839IL/0710 ( 250mg dose ) study opinion investigator may benefit gefitinib treatment . No 14 day lapse gefitinib treatment patient complete precede gefitinib clinical study begin study except agree AstraZeneca physician . Any evidence clinically active interstitial lung disease ( patient chronic , stable , radiographic change asymptomatic need exclude ) . In opinion investigator , evidence severe uncontrolled systemic disease ( e.g . unstable uncompensated respiratory , cardiac , hepatic renal disease ) . Withdrawal , time , precede gefitinib study . Concomitant use phenytoin , carbamazepine , rifampicin , barbiturate , St John 's Wort</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>130 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>